Related Experiment Video
Updated: Oct 3, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors
He-Jin Lee1, Soon Young Shin, Chan Choi
1Parkinson's Institute, Sunnyvale, California 94089, USA.
Abstract:
Mitochondrial dysfunction has been associated with Parkinson's disease. However, the role of mitochondrial defects in the formation of Lewy bodies, a pathological hallmark of Parkinson's disease has not been addressed directly. In this report, we investigated the effects of inhibitors of the mitochondrial electron-transport chain on the aggregation of alpha-synuclein, a major protein component of Lewy bodies. Treatment with rotenone, an inhibitor of complex I, resulted in an increase of detergent-resistant alpha-synuclein aggregates and a reduction in ATP level. Another inhibitor of the electron-transport chain, oligomycin, also showed temporal correlation between the formation of aggregates and ATP reduction. Microscopic analyses showed a progressive evolution of small aggregates of alpha-synuclein to a large perinuclear inclusion body. The inclusions were co-stained with ubiquitin, 20 S proteasome, gamma-tubulin, and vimentin. The perinuclear inclusion bodies, but not the small cytoplasmic aggregates, were thioflavin S-positive, suggesting the amyloid-like conformation. Interestingly, the aggregates disappeared when the cells were replenished with inhibitor-free medium. Disappearance of aggregates coincided with the recovery of mitochondrial metabolism and was partially inhibited by proteasome inhibitors. These results suggest that the formation of alpha-synuclein inclusions could be initiated by an impaired mitochondrial function and be reversed by restoring normal mitochondrial metabolism.
Insights
Impaired mitochondrial function can trigger alpha-synuclein aggregation, forming Lewy body-like inclusions in Parkinson's disease. Restoring mitochondrial metabolism can reverse this process.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Mitochondrial dysfunction is linked to Parkinson's disease (PD).
- The role of mitochondrial defects in Lewy body formation, a key PD pathology, remains unclear.
Purpose of the Study:
- To investigate the impact of mitochondrial electron-transport chain (ETC) inhibitors on alpha-synuclein aggregation.
- To explore the relationship between mitochondrial dysfunction and the formation of Lewy body-like inclusions.
Main Methods:
- Cells were treated with ETC inhibitors (rotenone, oligomycin) to induce mitochondrial dysfunction.
- Alpha-synuclein aggregation was assessed using biochemical assays and microscopy.
- ATP levels, aggregate co-localization, and thioflavin S staining were analyzed.
Main Results:
- Inhibitors of mitochondrial complex I (rotenone) and ATP synthase (oligomycin) increased alpha-synuclein aggregation and reduced ATP levels.
- Microscopy revealed the formation of perinuclear inclusions positive for ubiquitin and proteasome markers.
- Inclusions exhibited amyloid-like properties (thioflavin S-positive) and disappeared upon restoration of mitochondrial function.
Conclusions:
- Impaired mitochondrial function can initiate the formation of alpha-synuclein inclusions.
- These inclusions resemble Lewy bodies and their formation is linked to mitochondrial defects.
- Restoring mitochondrial metabolism offers a potential pathway for reversing alpha-synuclein aggregation in PD.

